AI-Funded Decision Support Software for Gastroenterology, Powered by Magentiq AI Technology
MAGENTIQ EYE's AI-Powered Software Advances Gastroenterology
In a significant development, MAGENTIQ EYE, an AI-based gastroenterology decision-support software company, has successfully completed its Series A funding round. This round was led by aMoon, Israel's largest HealthTech investment fund, and attracted participation from several other notable investors [1][2][3][4][5].
The primary focus of this funding will be to accelerate the commercialization and global expansion of MAGENTIQ EYE's flagship FDA- and CE-approved software, MAGENTIQ-COLO™. This innovative software enhances polyp detection and analysis during colonoscopies by providing real-time insights, polyp type and size estimation, and advanced AI-generated reports [1][2][3][4][5].
Looking ahead, MAGENTIQ EYE plans to expand its presence in the USA and Europe, targeting gastroenterology markets with regulatory clearances already secured [2][3][5]. Beyond these regions, the company aims to broaden global market access for its AI diagnostic tools [4].
The company's future plans also include extending AI diagnostics to related gastrointestinal conditions such as ulcerative colitis, Barrett’s esophagus dysplasia, and gastric intestinal metaplasia through ongoing clinical trials [1][4].
The involvement of aMoon's partner, Roy Wiesner, joining MAGENTIQ EYE’s board, adds strategic guidance to support innovation and scaling globally [1][3][5]. With this investment, MAGENTIQ EYE is poised to evolve its AI-powered gastroenterology software into a broader clinical decision-support platform with expanded features and worldwide commercial reach, establishing itself as a leading AI co-pilot for gastroenterologists in the US, Europe, and beyond [1][2][5].
It's worth noting that MAGENTIQ-COLO™ offers a comprehensive set of features, setting it apart in the market as the most accurate AI-powered colonoscopy solution [6]. Moreover, the software is flexible across GI and laparoscopic applications, making it a versatile tool for healthcare professionals.
The cost-effectiveness and scalability of MAGENTIQ EYE's solution have also garnered interest from major strategic players, who are looking to collaborate with the company [7]. This investment by aMoon reflects their commitment to backing transformative health tech solutions [8].
In addition to aMoon, Norgine Ventures BV (Netherlands), Nina Capital (EU & USA), Namarel Ventures SL (Spain), Nova Capital (Italy), and private investors Sake Bosch and Roon Doornink (USA) also participated in the funding round [1][3].
The proceeds from this funding round will support further development and commercial growth in the USA, Europe, and globally through partnerships with industry leaders [2][5]. This investment will help MAGENTIQ EYE accelerate innovation and market access, ensuring that its AI-powered software continues to improve healthcare outcomes for patients worldwide.
References: [1] https://www.prnewswire.com/news-releases/magentique-eye-completes-series-a-funding-round-led-by-amoon-301604002.html [2] https://www.globenewswire.com/news-release/2022/08/10/2515913/0/en/MAGENTIQ-EYE-Raises-30-Million-to-Transform-Gastroenterology-Care-with-AI-Powered-Solution.html [3] https://www.calcalistech.co.il/local/articles/0,7340,L-3974338,00.html [4] https://www.timesofisrael.com/israels-amoon-leads-30-million-series-a-round-for-ai-based-gastroenterology-company/ [5] https://www.jpost.com/business/israels-amoon-leads-30-million-series-a-round-for-ai-based-gastroenterology-company-678624 [6] https://www.healthcareitnews.com/news/israels-magentique-eye-aims-improve-adenoma-detection-rates-ai-powered-colonoscopy-solution [7] https://www.calcalistech.co.il/local/articles/0,7340,L-3974338,00.html [8] https://www.jpost.com/business/israels-amoon-leads-30-million-series-a-round-for-ai-based-gastroenterology-company-678624
- Science conducted in clinical trials could lead to the application of Magentiq Eye's technology in the detection and management of medical conditions like ulcerative colitis, Barrett’s esophagus dysplasia, and gastric intestinal metaplasia.
- As technology advances, AI-based software like Magentiq-COLO™, designed for gastroenterology decision-making, has the potential to become an integral part of health-and-wellness services, aiding in the analysis of various health conditions.
- The expansion of AI-powered software solutions beyond gastroenterology, such as Magentiq Eye's future plans, could leverage artificial-intelligence for improved diagnostics and treatment in the medical field.
